(RNLX) – Company Press Releases
-
Renalytix Announces Financing with Expected Size of up to $4 Million
-
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
-
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
-
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
-
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
-
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
-
Renalytix Reports Full Year Fiscal 2023 Results
-
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
-
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
-
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
-
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
-
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
-
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
-
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
-
KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
-
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
-
Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
-
New Published Real-World Evidence Shows KidneyIntelX™ Utility
-
New Published Real-World Evidence Shows KidneyIntelX™ Utility
-
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
-
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
-
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
-
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
-
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
-
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Renalytix announces a c.$20.3 million private placement
-
Renalytix announces a c.$20.3 million private placement
-
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
-
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
-
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
-
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
-
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
-
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
-
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
-
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
-
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
-
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
-
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
-
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
-
Renalytix to Present at Stifel Healthcare Conference
-
Renalytix to Present at Stifel Healthcare Conference
-
Renalytix Reports Full Year Fiscal 2022 Results
-
Renalytix Reports Full Year Fiscal 2022 Results
-
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
Back to RNLX Stock Lookup
